Skip to main content
. 2021 Apr 23;11:8816. doi: 10.1038/s41598-021-88086-x

Figure 3.

Figure 3

Showed Kaplan–Meier survival curve of critically ill COVID-19 patients, (A) for patients who received Toclizumab compared to those received pulse Dexamethasone (P = 0.002). (B) for patients with CT Chest showing Ground glass opacities (GGO) compared with bilateral consolidation, (P < 0.0001). (C) patients who do not need vasopressors at admission and those who need vasopressors at admission (P < 0.0001). (D) patients on mechanical ventilation compared to those on Non-invasive ventilation (P < 0.0001).